🎁 Black Friday: up to 50% off of annual plans
ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
0.8663
-0.0137 (-1.56%)
At close: Nov 20, 2026, 4:00 PM EST
0.9000
+0.0337 (3.89%)
After-hours: Nov 20, 2026, 4:10 PM EST

Company Description

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.

The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is based in Fremont, California.

ABVC BioPharma, Inc.
ABVC BioPharma logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees19
CEOUttam Patil

Contact Details

Address:
44370 Old Warm Springs Boulevard
Fremont, California 94538
United States
Phone510 668 0881
Websiteabvcpharma.com

Stock Details

Ticker SymbolABVC
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1173313
CUSIP Number00091F304
ISIN NumberUS00091F3047
Employer ID26-0014658
SIC Code2834

Key Executives

NamePosition
Dr. Uttam Yashwant Patil Ph.D.Chief Executive Officer and Interim Chief Financial Officer
Eugene JiangChairman and Chief Business Officer
Dr. Tsung-Shann Jiang EMBA, Ph.D.Chief Scientific Officer, Chief Strategy Officer and Director

Latest SEC Filings

DateTypeTitle
Nov 16, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 13, 2026424B4Prospectus
Nov 13, 2026424B4Prospectus
Nov 13, 2026424B4Prospectus
Nov 13, 2026424B4Prospectus
Nov 12, 2026S-3/A[Amend] Registration statement under Securities Act of 1933
Nov 10, 202610-QQuarterly Report
Nov 10, 2026DNotice of Exempt Offering of Securities
Nov 2, 20268-KCurrent Report
Sep 29, 2026DEF 14AOther definitive proxy statements
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides